Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life - 2I took my shoes off and went for a barefoot hike. I couldn’t believe what happened next
- 3Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- 4The Development of Shipping: Controlling Towards a More Associated Future
- 5An Investigate of 6 Creative Specialty Mixed drinks
- Monetary Strengthening: Assuming Command over Your Cash
- Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds
- Step by step instructions to Contrast Lab Jewels and Regular Ones
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- German politician urges more face-to-face interaction in digital age
- A Manual for Extravagant Vehicles Available in 2024
- With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
